AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY20 results · Jul–Sep 2019
AstraZeneca Pharma India reported revenue from operations of ₹208.48 crore (up 29.2% from Q2 FY19) and net profit of ₹14.42 crore (up 57.9% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a standalone basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 208.48 | 161.36 | +29.2% | 204.56 | +1.9% |
| Other income | 3.16 | 3.35 | −5.8% | 2.99 | +5.7% |
| Total income | 211.64 | 164.72 | +28.5% | 207.55 | +2.0% |
| Profit before tax | 31.80 | 14.44 | +120.1% | 33.63 | −5.5% |
| Net profit for the period | 14.42 | 9.13 | +57.9% | 21.52 | −33.0% |
| EPS, basic (₹) | 5.77 | 3.65 | +57.8% | 8.61 | −33.0% |
| Net margin (%) | 6.9 | 5.7 | 10.5 |
Standalone
- Filed with BSE
- 12 Nov 2019, 15:57 IST
- Board meeting
- 11 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE